MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. - Wikidata - awgldk - TriplyDB

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.

http://www.wikidata.org/entity/Q33688421

about

c-Met as a Target for Personalized Therapy Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression.Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.MET in gastric cancer--discarding a 10% cutoff rule Isothiocyanatostilbenes as novel c-Met inhibitors.Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.In silico dissection of miRNA targetome polymorphisms and their role in regulating miRNA-mediated gene expression in esophageal cancer.C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome.Prognostic Value of C-met Expression in Cholangiocarcinoma.miR-148a-3p suppresses epithelial ovarian cancer progression primarily by targeting c-Met.MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells

P2860

Q26775483-912AD7FF-BB70-4BFD-AF97-CA8176201D0A Q28081193-0ACEFD5E-8B63-4561-844D-C55E52FE6332 Q35626803-21791374-1A2B-4A74-8E3A-ADAB8F6E36C8 Q36413660-42A095E0-60C1-4328-B29C-FCB7486824E9 Q36554574-C2E87E86-7728-40F0-ABF8-13B0409AE3A9 Q36562316-6A145D76-3DB1-4C45-BE20-0568F24A75D3 Q38263575-E7A0AA57-AA54-4827-ACDB-07B4687A952A Q38831897-FB15B31D-79BE-476D-A69B-29265547C04B Q39866108-C7CF6884-052A-4500-9F1B-602D50C49E16 Q41073453-308E8DE5-369D-4564-95C0-179FF31FAB81 Q52608483-D575DF78-765F-4562-9632-2CC16099EE2F Q55491411-C1B95223-98B3-4F2D-A371-1B8CA64CECFF Q58573393-E6608254-7AAB-4A1B-9171-BB696AAB144F

P2860

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.

http://www.wikidata.org/entity/Q33688421

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

MET aberrations and c-MET inhi ...... eal cancers in a phase I unit.

@ast

MET aberrations and c-MET inhi ...... eal cancers in a phase I unit.

@en

type

label

MET aberrations and c-MET inhi ...... eal cancers in a phase I unit.

@ast

MET aberrations and c-MET inhi ...... eal cancers in a phase I unit.

@en

prefLabel

MET aberrations and c-MET inhi ...... eal cancers in a phase I unit.

@ast

MET aberrations and c-MET inhi ...... eal cancers in a phase I unit.

@en

P1433

Q33688421-BA4089BA-D9D0-41B9-A28D-9FF9816FDB1F

P1476

Q33688421-E585A8B0-203F-43B2-BE35-EB56A10EC983

P2093

Q33688421-01DB028F-F390-48C0-999B-28549E5F1411

Q33688421-28F72A1D-6FB9-4DD2-8595-D3C28766EAEA

Q33688421-40555790-6518-4295-B74F-D9D482411216

Q33688421-461321FC-E75C-430C-8E25-5F66416A702C

Q33688421-61B6487E-41CA-4DAE-8B98-44BC1F85B907

Q33688421-620FFEE7-5851-4807-8428-7F8730D309F8

Q33688421-68363513-88CD-4710-8E52-9B2CE63776A7

Q33688421-73BFB1B4-E1BD-4C3E-B868-2DD90B82A404

Q33688421-9088DF76-CCC7-4A13-A821-885C0D72A471

Q33688421-920A6CE6-B294-42E4-AB92-37C9993B0E26

P2860

Q33688421-32E87F61-D567-4584-ACEA-666BBD2E9140

Q33688421-3ABA5CAB-9955-461A-9BC9-83F90E04E66D

Q33688421-47780987-3BB8-485A-A243-7E35710563D2

Q33688421-4AD93920-4582-4052-9184-040A0AEAC293

Q33688421-5257CCDD-1DD1-4096-8BA0-79F4358BEBB3

Q33688421-5C213328-F7F9-4EAD-8B65-A9820493EAF6

Q33688421-5E34B81D-74A4-4BF4-858B-8308D975DDB8

Q33688421-67AD4594-A255-4ECA-B24F-55B2C0FF2AC9

Q33688421-706693A2-FB15-4BA8-85D5-511C47AF15C9

Q33688421-76DBA02F-DB16-4395-963A-7311C5F9ACA4

P304

Q33688421-4BAF71A3-6249-481C-8435-5D35AD688989

P31

Q33688421-30B030B2-76E8-48D4-9FC6-E39CC3BAE3D0

P356

Q33688421-03026804-D03B-4CE8-9FF9-7EEF673E4A08

P407

Q33688421-8DEEEA0D-0C53-4A78-B822-6A0E531F5B5C

P433

Q33688421-D3254083-C3DA-484B-B393-CF6C6D1319A3

P478

Q33688421-FB75B90E-E158-4E3A-9B3E-2924E5C9C0F2

P50

Q33688421-04D5BBC8-5BD8-4460-B30D-1A39E589DB74

Q33688421-636218A1-B01C-46E1-AB75-DA83460253A1

Q33688421-93628087-89BD-4CD7-B6AE-1FAEC80FF92A

P577

Q33688421-5AAD0E22-9543-4B2E-A9AB-58387FD98DA6

P5875

Q33688421-F1E0A046-FBBD-4DE0-8907-633E986A675D

P698

Q33688421-B75F969B-A988-4826-B209-73AF9A2873ED

P932

Q33688421-45EEC824-D947-469F-A4DD-30304C858EA1

P356

ONCOTARGET.1828

P1433

P1476

MET aberrations and c-MET inhi ...... eal cancers in a phase I unit.

@en

P2093

Chad Tang

http://www.w3.org/2001/XMLSchema#string

David S Hong

http://www.w3.org/2001/XMLSchema#string

Debora de Melo Gagliato

http://www.w3.org/2001/XMLSchema#string

Denis L Fontes Jardim

http://www.w3.org/2001/XMLSchema#string

Gerald S Falchook

http://www.w3.org/2001/XMLSchema#string

Jaffer Ajani

http://www.w3.org/2001/XMLSchema#string

Jennifer J Wheler

http://www.w3.org/2001/XMLSchema#string

Kenneth Hess

http://www.w3.org/2001/XMLSchema#string

Mariela Blum Murphy

http://www.w3.org/2001/XMLSchema#string

Ralph Zinner

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor

Drug development of MET inhibitors: targeting oncogene addiction and expedience.

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors.

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

P304

1837-1845

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.1828

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Funda Meric-Bernstam

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261756409

http://www.w3.org/2001/XMLSchema#string

P698

24742823

http://www.w3.org/2001/XMLSchema#string

P932

4039117

http://www.w3.org/2001/XMLSchema#string